NCOA4 - 9a
目录号 : GC26219NCOA4 - 9a 是一种铁蛋白自噬抑制剂，能够抑制erastin诱导的铁死亡，EC50值为0.29μM。
Cas No.:2650557-72-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
NCOA4 - 9a is an inhibitor of ferritinophagy that inhibits erastin-induced ferroptosis, with an EC50 value of 0.29μM[1]. NCOA4 - 9a blocks ferroptosis by reducing the amount of bioavailable intracellular ferrous iron through disrupting the NCOA4–FTH1 protein–protein interaction[2]. NCOA4 - 9a is widely used to interfere with the ferritin autophagy process, reduce the release of iron ions, and delay the neuronal death in the rat hippocampus[3].
In vitro, NCOA4 - 9a treatment (0.5μM) for 36 hours significantly reversed the upregulation of lipid ROS levels in HCT-116 cells induced by sodium butyrate (NaB)[4]. 10μM NCOA4 - 9a treatment for 4 hours significantly increased the expression of FTH1 protein in the goat sperm model of cryopreservation and enhanced sperm survival[5]. NCOA4 - 9a treatment (0.5μM; 24h) reversed the cell death of human periodontal ligament cells (hPDLCs) significantly decreased under the stimulation of compressive force (CF) and IL-1β[6]. NCOA4 - 9a pretreatment for 2 hours (2.5μM) reduced the expression of the NP protein of PR8 H1N1 virus in A549 cells and inhibited the replication of PR8 H1N1 virus[7].
In vivo, NCOA4 - 9a treatment via daily intraperitoneal injection (10mg/kg) for 5 consecutive days significantly inhibited the growth of leukemia tumors in the murine patient-derived xenograft (PDX) models of acute myeloid leukemia (AML), without affecting the body weight of the mice[8].
References:
[1] Fang Y, Chen X, Tan Q, et al. Inhibiting ferroptosis through disrupting the NCOA4–FTH1 interaction: a new mechanism of action[J]. ACS central science, 2021, 7(6): 980-989.
[2] Larrue C, Mouche S, Angelino P, et al. Ferritinophagy Is a Druggable Vulnerability of Quiescent Leukemic Stem Cells[J]. Blood, 2023, 142: 407.
[3] Chen J, Yan L, Zhang Y, et al. Maternal exposure to nanopolystyrene induces neurotoxicity in offspring through P53-mediated ferritinophagy and ferroptosis in the rat hippocampus[J]. Journal of Nanobiotechnology, 2024, 22(1): 651.
[4] Liu L, Liu Y, Zhou X, et al. Sodium butyrate induces ferroptosis in colorectal cancer cells by promoting NCOA4-FTH1-mediated ferritinophagy[J]. International Immunopharmacology, 2025, 163: 115188.
[5] Hai E, Li B, Song Y, et al. Superoxide anion-induced ferritinophagy is involved in ferroptosis occurrence of cashmere goat sperm during cryopreservation[J]. Journal of Integrative Agriculture, 2025.
[6] Liu L, Li D, Zhou Z, et al. Inhibition of NCOA4/FTH1-mediated ferritinophagy attenuates ferroptosis in PDLCs and alleviates orthodontically induced inflammatory root resorption[J]. Progress in Orthodontics, 2025, 26(1): 43.
[7] Ouyang A, Chen T, Feng Y, et al. The hemagglutinin of influenza A virus induces ferroptosis to facilitate viral replication[J]. Advanced Science, 2024, 11(39): 2404365.
[8] Larrue C, Mouche S, Angelino P, et al. Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models[J]. Science Translational Medicine, 2024, 16(757): eadk1731.
NCOA4 - 9a是一种铁蛋白自噬抑制剂，能够抑制erastin诱导的铁死亡，EC50值为0.29μM[1]。NCOA4 - 9a通过破坏NCOA4–FTH1蛋白-蛋白相互作用，减少细胞内生物可利用的二价铁含量，从而阻断铁死亡[2]。NCOA4 - 9a被广泛用于干扰铁蛋白自噬过程，减少铁离子释放，并延缓大鼠海马中的神经元死亡[3]。
在体外，使用0.5μM的NCOA4 - 9a处理36小时，显著逆转了丁酸钠（NaB）诱导的HCT-116细胞中脂质ROS水平的上调[4]。10μM的NCOA4 - 9a处理4小时，显著提高了冷冻保存的山羊精子模型中FTH1蛋白的表达，并增强了精子存活率[5]。NCOA4 - 9a处理（0.5μM；24小时）逆转了在压缩力（CF）和IL-1β刺激下显著降低的人牙周膜细胞（hPDLCs）的细胞死亡[6]。NCOA4 - 9a预处理2小时（2.5μM）降低了PR8 H1N1病毒的NP蛋白在A549细胞中的表达，并抑制了PR8 H1N1病毒的复制[7]。
在体内，每日腹腔注射NCOA4 - 9a（10mg/kg），连续5天，显著抑制了急性髓系白血病（AML）患者来源异种移植（PDX）小鼠模型中白血病肿瘤的生长，且未影响小鼠的体重[8]。
| Cell experiment [1]: | |
Cell lines | Human periodontal ligament stem cells (hPDLCs) |
Preparation Method | hPDLCs were seeded at a density of 1×105 cells per well in a 6-well plate and cultured until the cell confluence reached 80%. To apply compressive force to the hPDLCs, a layer of glass sheet was placed on the cells, and a container with metal balls containing heavy metals was used to adjust the compressive force by changing the number of metal balls. Additionally, at a compressive force of 2g/cm2, 20ng/ml of IL-1β was added to the hPDLCs for 24 hours, and NCOA4 - 9a (0.5µM) was used for treatment simultaneously. Then, cell viability was analyzed. |
Reaction Conditions | 0.5µM; 24h |
Applications | NCOA4 - 9a treatment reversed the phenomenon that cell viability of hPDLCs significantly decreased under the stimulation of CF and IL-1β. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley (SD) rats |
Preparation Method | Male Sprague-Dawley (SD) rats weighing 180-220g were housed individually under standard conditions of temperature and humidity, and a 12h light-dark cycle, with free access to food and water. Rats were anesthetized with intraperitoneal injection of phenobarbital (60mg/kg). The left common carotid artery and external carotid artery were separated and ligated through a median cervical incision, and the pterygofrontal artery was separated as well. An arterial clamp was placed in the proximal and distal carotid arteries, and a 4-0 monofilament nylon suture was inserted through the incision, to a depth of 17-20mm. The filament was withdrawn to restore blood flow (reperfusion) after 1.5h of middle cerebral artery occlusion (MCAO). All the SD rats subjected to MCAO were randomly divided into four groups (n=18 per group). Vehicle, Fer-1 (10mg/kg), or NCOA4 - 9a (10mg/kg) was administered by intraperitoneal injection 0.5h before and 2h after MCAO occlusion. All the sham-operated control rats were performed the same surgical procedure without insertion of a filament. Collect brain tissue for analysis. |
Dosage form | 10mg/kg for twice; i.p. |
Applications | NCOA4 - 9a treatment alleviate cerebral ischemic injury in rats and reduce the levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). |
References: | |
| Cas No. | 2650557-72-3 | SDF | |
| 分子式 | C27H28FN5 | 分子量 | 441.54 |
| 溶解度 | DMSO: 40mg/mL, Need ultrasonic; Insoluble in water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2648 mL | 11.324 mL | 22.648 mL |
| 5 mM | 453 μL | 2.2648 mL | 4.5296 mL |
| 10 mM | 226.5 μL | 1.1324 mL | 2.2648 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet